Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Larkin JMG"'
Autor:
Larkin Jmg., P.A. Ascierto, Michael Millward, Maurice Lobo, J.-J. Grob, Jeffrey S. Weber, M. Del Vecchio, Jose Lutzky, Marcus O. Butler, Fernandez Ama., V. de Pril, Helen Gogas, Ivan Marquez-Rodas, Mario Mandalà, Michael Schenker, A.M. Di Giacomo, Charles Lance Cowey, S. Dalle, Mark R. Middleton, V. Chiarion-Sileni
Publikováno v:
Journal of Clinical Oncology. 37:9584-9584
9584 Background: In both previous 18- and 24-month follow-up reports from CheckMate 238, NIVO demonstrated significantly longer recurrence-free survival (RFS) than ipilimumab (IPI) in patients (pts) with resected stage IIIB/C or stage IV melanoma. He
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66f5713eb9752105c53512a3b775356c
https://doi.org/10.1200/jco.2019.37.15_suppl.9584
https://doi.org/10.1200/jco.2019.37.15_suppl.9584
Autor:
Ruth Asher, Mark R. Middleton, L Collins, Richard Lisle, Ottensmeier Chh., Paul Nathan, Larkin Jmg., A Thomason, Ruth Plummer, Avinash Gupta, M Churchman, Sarah Danson, Milensu Shanyinde, Sharon Love, Anna Schuh, Paul Lorigan
Publikováno v:
Journal of Clinical Oncology. 31:9068-9068
9068 Background: Inhibitors of mutant BRAF have transformed the treatment of melanoma for the 40% of patients whose tumors harbor V600 mutations. ERK1/2 is constitutively active in melanoma cells regardless of mutation status, and plays key roles in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a5ee448e1274a532cfc85cf31a265de
https://doi.org/10.1200/jco.2013.31.15_suppl.9068
https://doi.org/10.1200/jco.2013.31.15_suppl.9068
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Suárez C; Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Larkin JMG; The Royal Marsden Hospital, London, United Kingdom., Patel P; Nottingham University Hospital NHS Trust, Nottingham, United Kingdom., Valderrama BP; Hospital Universitario Virgen del Rocío, Seville, Spain., Rodriguez-Vida A; Hospital del Mar-CIBERONC, IMIM Research Institute, Barcelona, Spain., Glen H; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Thistlethwaite F; The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom., Ralph C; St. James's Institute of Oncology, University of Leeds, Leeds, United Kingdom., Srinivasan G; Mid Essex Hospital Services NHS Trust, Broomfield, United Kingdom., Mendez-Vidal MJ; Reina Sofía University Hospital, Cordoba, Spain., Hartmaier R; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD., Markovets A; Translational Medicine, Oncology R&D, AstraZeneca, Gaithersburg, MD., Prendergast A; Barts ECMC, Barts Cancer Institute, Queen Mary University London, London, United Kingdom., Szabados B; Barts ECMC, Barts Cancer Institute, Queen Mary University London, London, United Kingdom., Mousa K; Barts ECMC, Barts Cancer Institute, Queen Mary University London, London, United Kingdom., Powles T; Barts ECMC, Barts Cancer Institute, Queen Mary University London, London, United Kingdom.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 May 10; Vol. 41 (14), pp. 2493-2502. Date of Electronic Publication: 2023 Feb 21.
Autor:
Serra-Bellver P; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: p.serra@nhs.net., Versluis JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Oberoi HK; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Zhou C; Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, United Kingdom., Slattery TD; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom., Khan Y; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom., Patrinely JR; Department of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Pires da Silva I; Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Westmead and Blacktown Hospital, Sydney, Australia., Martínez-Vila C; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Cook N; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, United Kingdom., Graham DM; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, United Kingdom., Carlino MS; Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Westmead and Blacktown Hospital, Sydney, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia., Arance AM; Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain., Johnson DB; Department of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Long GV; Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia., Pickering L; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom., Larkin JMG; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Lorigan P; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, United Kingdom.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Nov; Vol. 176, pp. 121-132. Date of Electronic Publication: 2022 Oct 07.
Autor:
Sarnaik AA; H. Lee Moffitt Cancer Center, Tampa, FL., Hamid O; The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Los Angeles, CA., Khushalani NI; H. Lee Moffitt Cancer Center, Tampa, FL., Lewis KD; University of Colorado Cancer Center-Anschutz Medical Campus, Aurora, CO., Medina T; University of Colorado Cancer Center-Anschutz Medical Campus, Aurora, CO., Kluger HM; Yale University School of Medicine, Smilow Cancer Center, New Haven Hospital, New Haven, CT., Thomas SS; University of Florida Health Cancer Center at Orlando Health, Orlando, FL., Domingo-Musibay E; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Pavlick AC; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY., Whitman ED; Atlantic Health System Cancer Care, Morristown, NJ., Martin-Algarra S; Clínica Universidad de Navarra, Pamplona, Spain., Corrie P; Cambridge University Hospitals NHS Foundation Trust-Addenbrooke's Hospital, Cambridge, United Kingdom., Curti BD; Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR., Oláh J; University of Szeged-Albert Szent-Györgyi Health Center, Szeged, Hungary., Lutzky J; Mount Sinai Comprehensive Cancer Center, Miami, FL., Weber JS; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY., Larkin JMG; Royal Marsden NHS Foundation Trust, London, United Kingdom., Shi W; Iovance Biotherapeutics Inc, San Carlos, CA., Takamura T; Iovance Biotherapeutics Inc, San Carlos, CA., Jagasia M; Iovance Biotherapeutics Inc, San Carlos, CA., Qin H; Iovance Biotherapeutics Inc, San Carlos, CA., Wu X; Iovance Biotherapeutics Inc, San Carlos, CA., Chartier C; Iovance Biotherapeutics Inc, San Carlos, CA., Graf Finckenstein F; Iovance Biotherapeutics Inc, San Carlos, CA., Fardis M; Iovance Biotherapeutics Inc, San Carlos, CA., Kirkwood JM; Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA., Chesney JA; James Graham Brown Cancer Center, University of Louisville, Louisville, KY.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Aug 20; Vol. 39 (24), pp. 2656-2666. Date of Electronic Publication: 2021 May 12.